OT mobile menu

Search form


Breast Cancer Targets

Treating Bone Loss in Breast Cancer

A new study has identified how bones get damaged from breast cancer and researchers are developing a new drug to mitigate this problem. Image © JKSippapas/Shutterstock.com


Breast Cancer Targets

The 70-gene test could aid clinicians and patients in determining the optimal treatment course for breast cancer patients with a very low risk of death from the disease.

A new clinical trial is recruiting to determine whether a breath testing device can aid in the diagnosis of breast cancer.

Results from a nationwide clinical trial, which were presented at the 2017 ASCO Annual Meeting, indicate that adding pembrolizumab to standard therapy before surgery offers the potential for improving outcomes in this patient population.

Atezolizumab was approved for treating patients with metastatic non–small-cell lung cancer who experienced disease progression during or following platinum-containing chemotherapy. Now, it turns out this agent may have a role in combating breast cancer.

A new study is suggesting that testing for variants in seven cancer-associated genes followed by risk-reduction management could cost-effectively improve life expectancy for women at risk for hereditary breast cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.


Subscribe to Breast Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.